> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Updated FDA Hepatic Function Guidance Explained
- URL: https://www.fdaweb.com/updated-fda-hepatic-function-guidance-explained/
- Published: 2026-11-18T22:13:00.000Z
- Updated: 2026-11-18T22:13:00.000Z
- Author: David McFarland
- Tags: Drugs

The FDA Guidance Recap Broadcast recently explained updated agency guidance on “Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage.” Office of Clinical Pharmacology regulatory scientific reviewer **Martina Sahre** first [discussed](https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-pharmacokinetics-patients-impaired-hepatic-function-study-design-data?ref=fdaweb.com) the importance of studying the effect of hepatic impairment in drug development.

She then described three key updates in the draft guidance:

- updated recommendations on when to conduct a dedicated pharmacokinetic study in patients with hepatic impairment;
- addition of the National Cancer Institute Organ Dysfunction Working Group criteria as an option to classify hepatic impairment for patients with cancer, except for patients with hepatobiliary cancer; and
- replacement of the separate section on reduced study designs with general study design considerations for all categories of hepatic impairment.

Asked for key takeaways on the updated draft, Sahre presented:

- the importance of understanding how hepatic impairment affects a drug’s pharmacokinetics and/or pharmacodynamics so appropriate dosage recommendations can be developed;
- assessing the effect of hepatic impairment early in drug development, to facilitate the inclusion of patients with hepatic impairment in clinical trials and ensure that the findings apply to the population likely to use the drug; and
- while the Child-Pugh classification continues to be the recommended approach for subjects with cirrhosis, the draft also discusses the National Cancer Institute criteria for subjects with cancer, and encourages the assessment of other relevant markers to explore their correlation with pharmacokinetic changes.

Sahre said comments on the draft are encouraged and would be particularly helpful before 12/1 so they can be considered when the agency starts work to finalize the guidance.